Table 1.
Clinicopathological variables | No (%) | No. of patients (%) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Kind1 expression | Kind2 expression | Kind3 expression | ||||||||
Low | High | p value | Low | High | p value | Low | High | p value | ||
Total | 438 | 377 (86.1) | 61 (13.9) | 364 (83.1) | 74 (16.9) | 165 (37.7) | 273 (62.3) | |||
SBR histological grade | ||||||||||
I | 55 | 52 (94.5) | 3 (5.5) | 41 (74.5) | 14 (25.5) | 23 (41.8) | 32 (58.2) | |||
II | 222 | 202 (91.0) | 20 (9.0) | 182 (82.0) | 40 (18.0) | 90 (40.5) | 132 (59.5) | |||
III | 153 | 118 (77.1) | 35 (22.9) | 0.0002 | 134 (87.6) | 19 (12.4) | NS | 49 (32.0) | 104 (68.0) | NS |
Lymph node status | ||||||||||
0 | 115 | 93 (80.9) | 22 (19.1) | 99 (86.1) | 16 (13.9) | 48 (41.7) | 67 (58.3) | |||
1–3 | 229 | 201 (87.8) | 28 (12.2) | 190 (83.0) | 39 (17.0) | 86 (37.6) | 143 (62.4) | |||
> 3 | 93 | 82 (88.2) | 11 (11.8) | NS | 75 (80.6) | 18 (19.4) | NS | 31 (33.3) | 62 (66.7) | NS |
Macroscopic tumor size | ||||||||||
≤ 25 mm | 214 | 185 (86.4) | 29 (13.6) | 174 (81.3) | 40 (18.7) | 81 (37.9) | 133 (62.1) | |||
> 25 mm | 216 | 185 (85.6) | 31 (14.4) | NS | 185 (51.5) | 31 (43.7) | NS | 80 (37.0) | 136 (63.0) | NS |
ER status | ||||||||||
Negative | 111 | 67 (60.4) | 44 (39.6) | 91 (82.0) | 20 (18.0) | 32 (28.8) | 79 (71.2) | |||
Positive | 327 | 310 (94.8) | 17 (5.2) | p < 0.0000001 | 273 (83.5) | 54 (16.5) | NS | 133 (40.7) | 194 (59.3) | 0.03 |
PR status | ||||||||||
Negative | 184 | 139 (75.5) | 45 (24.5) | 153 (83.2) | 31 (16.8) | 61 (33.2) | 123 (66.8) | |||
Positive | 254 | 238 (93.7) | 16 (6.3) | p < 0.0000001 | 211 (83.1) | 43 (16.9) | NS | 104 (40.9) | 150 (59.1) | NS |
HER2 status | ||||||||||
Negative | 345 | 295 (85.5) | 50 (14.5) | 288 (83.5) | 57 (16.5) | 137 (39.7) | 208 (60.3) | |||
Positive | 93 | 82 (88.2) | 11 (11.8) | NS | 76 (81.7) | 17 (18.3) | NS | 28 (30.1) | 65 (69.9) | NS |
Molecular subtypes | ||||||||||
ER- PR- HER2- (Triple Neg) | 64 | 29 (45.3) | 35 (54.7) | 54 (84.4) | 10 (15.6) | 18 (28.1) | 46 (71.9) | |||
ER- PR- HER2+ (ERBB2) | 42 | 34 (81.0) | 8 (19.0) | 32 (76.2) | 10 (23.8) | 9 (21.4) | 33 (78.6) | |||
ER+ PR+ HER2- Ki67low (Lum A) | 213 | 202 (94.8) | 11 (5.2) | 173 (81.2) | 40 (18.8) | 98 (46.0) | 115 (54.0) | |||
ER+ PR+ HER2+ or Ki67high (Lum B) | 119 | 112 (94.1) | 7 (5.9) | p < 0.0000001 | 105 (88.2) | 14 (11.8) | NS | 40 (33.6) | 79 (66.4) | 0.003 |
Statistical analyses were performed by means of a chi-squared test (NS: not significant)